Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors

African Journal of Biotechnology

Volumn 9, Issue 25, 2010, Pages 3923-3931

  Noureen, Nighat ^a   Kalsoom, Saima ^b   Rashid, Hamid ^a  

^a CAPITAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Anticancer; Cancer; Histone deacetylase inhibitors; Histone deacetylases; Pharmacophore; Target; Therapeutic

Indexed keywords

BENZAMIDE DERIVATIVE; BIPHENYL DERIVATIVE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; LIGAND; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE;

ARTICLE; CHEMICAL MODEL; COMPUTER MODEL; COMPUTER PROGRAM; CONFORMATION; DRUG SCREENING; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DOCKING; PHARMACOPHORE; PREDICTION; TREATMENT PLANNING;

EID: 77954867763     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chen JS, Faller DV, Spanjaard RA (2003). Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr. Cancer Drug Targets, 3: 219-236.
2. Chen PC, Patil V, Guerrant W, Green P, Oyelere AK (2008a). Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg. Med. Chem. 16: 4839-4853.
3. Chen Y, Jiang YJ, Zhou JW, Yu QS, You QD (2008b). Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J. MGM, 26: 1160-1168.
4. Chen Y, Li H, Tang W, Zhu C, Jiang Y, Zou J, Yu Q, You Q (2009). 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur. J. Med. Chem. Pp. 1-9.
5. Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, Cesare MD, Zunino F (2009). Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur. J. Med. Chem pp. 1-13
6. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P (1999). Anticancer agents targeting signalling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst. 91: 1281-1287.
7. How to use Jmol to study and present molecular structures, ISBN 978-1-84799-259-8 Lulu Enterprises: Morrisville, NC, USA © Angel Herráez, 2007.
8. Humphrey W, Dalke A, Schulten K (1996).VMD: Visual molecular dynamics. J. Mol. Graphics, 14: 33-38.
9. Jmol: an open-source Java viewer for chemical structures in 3D. http://www.jmol.org/
10. Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, Loidl P (1999). Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 42: 4669-4679.
11. Juvale DC, Kulkarni VV, Deokar HS, Wagh NK, Padhye SB, Kulkarni VM (2006).3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. Org. Biomol. Chem. 4: 2858-2868.
12. Karagiannis TC, El-Osta A (2007). Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?. Leukemia. 21: 61-65.
13. Katritzky AR, Slavov SH, Dobchev DA, Karelson M (2007). Comparison between 2D and 3D-QSAR. QSAR Comb. Science, 26: p. 333.
14. Lavoie R, Bouchain G, Frechette S, Woo SH, Khalil EA, Leit S, Fournel M, Yan PT, Trachy-Bourget MC, Beaulieu C, Li Z, Besterman J, Delorme D (2001). Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 11(2001): 2847-2850.
15. Liqin Y, Fei L, Yadong C, Qidong Y (2009). Pharmacophore identification of hydroxamate HDAC 1 inhibitors. Chin. J. Chem. 27: 557-564.
16. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001). Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 1: 194-202
17. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, Brosch G (2001). 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors. J. Med. Chem. 44: 2069-2072.
18. Minucci S, Pelicci PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 6: 38-51.
19. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998). Automated docking using a Lamarkian Genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19(14): 1639-1662.
20. Qianbin L, Wenfang X (2005). Novel anticancer targets and drug discovery in post genomic age. Curr. Med.Chem- Anti-Cancer Agents, 5: 53-63.
21. Ragno R, Simeoni S, Valente S, Massa S, Mai A (2006). 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. J. Chem. Info. Model, 46: p. 1420.
22. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, Howell KL, Jung M, Kwon P, Trogani N, Walker H (2002). Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 45: 753-757.
23. Schuster D, Langer T (2005). The identification of ligand features essential for PXR activation by pharmacophore modeling. J. Chem. Info. Model, 45: p. 431.
24. Schuster D, Laggner C, Palusczak A, Hartmann RW, Langer T (2006). Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J. Chem. Info. Model, 46: p. 1301.
25. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedol H (1999). Essential drugs for cancer therapy: A world health organization consultation. Ann. Oncol. 10: 385-390.
26. Steindl TM, Schuster D, Wolber G, Laggner C, Langer T (2006). Highthroughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening. J. Comp. Aided Mol. Design, 20: 703-715.
27. Sternson SM, Wong JC, Grozinger CM, Schreiber SL (2001). Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 3: 4239-4242.
28. Suzuki T, Ando T, Tsuchiya K, Fukazawa N (1999). Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives. J. Med. Chem. 42: 3001-3003.
29. Vadivelan S, Sinha BN, Rambabu G, Boppana K, Jagarlapudi SA(2008). Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. J. Mol. Grap. Modeling, 26: p. 935.
30. Wagh NK, Deokar HS, Juvale DC, Kadam SS, Kulkarni VM (2006). 3DQSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation. Indian J. Biochem. Biophys. 43: p. 360.
31. Walkinshaw DR, Yang XJ (2008).Histone deacetylase inhibitors as novel anticancer therapeutics. Curr. Oncol. 15(5).
32. Woo SW, Frechette S, Khalil EA, Bouchain G, Vaisburg A, Bernstein N, Moradei O, Leit S, Allan M, Fournel M, Trachy-Bourget MC, Li Z, Besterman JM, Delorme D (2002). Structurally simple trichostatin Alike straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem. 45: 2877-2885.